Professional Essentials · Free · No registration
Spondyloarthritis: the clinical framework
Connect axial and peripheral disease without losing the distinctions that determine diagnosis and treatment.
Spondyloarthritis (SpA) is a family of related inflammatory disorders, not a single treatment pathway. Shared clinical features help clinicians recognize connections among sacroiliac or spinal inflammation, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis and inflammatory bowel disease (IBD). The useful next step is to identify which disease and which active domains explain this person’s presentation, while preserving uncertainty where the evidence is incomplete.
1. Describe the disease and its domains separately
Record the best-supported disease or context—axial SpA, psoriatic arthritis (PsA), reactive arthritis or IBD-associated disease—then document axial, peripheral and extra-musculoskeletal involvement. PsA can include both peripheral and axial manifestations; “peripheral SpA” should not erase its spinal component. An infection-linked episode may remain reactive arthritis or reveal an evolving phenotype during follow-up.
Within axSpA, radiographic and non-radiographic categories refer to whether definite sacroiliitis is present on plain radiographs. They do not measure current activity, symptom severity or treatment need. Non-radiographic disease is not invariably early disease, and progression is not inevitable. The ASAS nomenclature consensus favors the overarching term axSpA while retaining relevant distinctions. Also distinguish inflammation from structural damage and the patient’s experienced burden: a fused segment, active sacroiliitis and persistent pain are different observations.
Core principles across the SpA family → Open access
2. Use classification to organize evidence
Diagnosis integrates the time course, examination, competing explanations and pretest probability. Inflammatory back pain, HLA-B27, elevated CRP and imaging can each alter probability, but none is an independent diagnostic verdict. Normal CRP or negative HLA-B27 does not by itself exclude SpA. Psoriasis plus back pain is not automatically axial PsA; heel tenderness is not automatically inflammatory enthesitis.
The ASAS axial classification criteria were developed in a selected population with chronic back pain beginning before age 45. Their imaging and clinical routes classify research populations; their performance cannot be transferred unchanged to unselected back pain. CASPAR likewise requires inflammatory articular disease before its point system is applied. Preserve the difference between an absent test, a negative test and an uninterpretable test.
Do not let an established label suppress urgent alternatives. A hot joint may require aspiration for infection or crystals. A painful photophobic eye needs urgent ophthalmic assessment. New severe pain after trauma in an ankylosed spine raises concern for fracture; neurologic symptoms require urgent evaluation.
Write an assessment that another clinician can reconstruct: the inflammatory manifestations actually observed, the supporting investigations, the credible alternatives and the reason for diagnostic confidence. “Possible axial SpA with nonspecific sacroiliac edema” communicates a different state from a confirmed diagnosis with active inflammation. A referral threshold can appropriately be lower than a treatment threshold. When evidence is equivocal, choose a follow-up question—repeat examination, expert image review or evaluation of an associated condition—rather than repeatedly ordering the same broad panel. Uncertainty needs a plan, not a falsely precise probability.
Diagnosis and classification → Open demo · No registration
3. Ask imaging a defined question
Separate the questions of active inflammation, accumulated structural damage and an alternative cause of symptoms. Radiographs show structure but may be normal in axSpA without radiographic sacroiliitis. Dedicated sacroiliac MRI can assess inflammatory and structural lesions; a routine lumbar study is not an interchangeable examination. CT is useful for selected structural or fracture questions and requires attention to radiation.
Bone-marrow edema is not specific to inflammatory SpA. Primary MRI research demonstrated potentially misleading appearances in healthy participants, runners and postpartum women. Interpret lesion location, extent, depth, accompanying structural findings and technical quality alongside the clinical history. Ultrasound can clarify peripheral synovitis, tenosynovitis or entheseal abnormalities, but mechanical and age-related changes also occur.
ASAS imaging communication recommendations support meaningful clinical information in the request and a structured report. When imaging and the examination disagree, review the actual study and its question before ordering serial scans or escalating treatment.
Imaging lesions, pattern and probability → Professional access required
4. Match treatment to active disease
Education, exercise and rehabilitation are part of treatment throughout the course. The 2025 EULAR physical-activity update, published in 2026, supports integrating activity into care, adapted to capacity and barriers. Build achievable plans for mobility, strength and aerobic fitness, with modifications for active inflammation, damage and comorbidity.
NSAIDs may help when individual gastrointestinal, renal and cardiovascular risks permit. Conventional DMARDs have roles in peripheral inflammatory arthritis, particularly PsA, but are not established therapy for purely axial inflammation. The ASAS–EULAR framework links escalation to persistently active disease, prior treatment, relevant objective findings and patient factors. A high symptom score alone cannot identify the correct inflammatory target.
The ACR 2026 posted summary recognizes TNF and IL-17 inhibitors as initial biologic choices in adult axSpA, with selection shaped by associated disease and risk. For PsA, GRAPPA considers multiple domains together; a drug successful for skin or peripheral joints cannot be assumed effective for established axial disease. Check the particular agent’s indication and evidence.
Axial and peripheral treatment decisions → Professional access required
5. Let associated disease change the choice
Recurrent uveitis and active IBD can favor monoclonal TNF inhibitors over agents without comparable organ efficacy. Etanercept should not be assumed to treat IBD. IL-17 inhibition is generally unsuitable with active IBD, even when the musculoskeletal indication is attractive. Significant psoriasis may favor agents with strong skin efficacy, while bowel and axial requirements remain part of the same decision.
The EULAR PsA update explicitly incorporates skin and extra-musculoskeletal manifestations into medication selection. Coordinate with dermatology, ophthalmology and gastroenterology rather than treating each organ in isolation. Reactive arthritis needs a separate decision about current infection: antimicrobial treatment and control of synovitis serve different purposes.
Before targeted therapy, assess infections, vaccines, pregnancy plans and drug-specific contraindications. JAK inhibitors require particular attention to cardiovascular, thrombotic and malignancy risk. The 2024 EULAR reproduction update, published in 2025, supports medication-specific planning; pregnancy, breastfeeding and paternal exposure are not interchangeable safety questions.
When the eye, bowel or skin redirects therapy → Professional access required
6. Make follow-up test the explanation
Track inflammation, function and treatment burden separately. ASDAS can organize axial activity assessment; BASDAI is patient-reported and is not an objective inflammation test. In PsA, a joint-focused score can miss active skin, entheses, dactylitis or axial disease. Inspect clinically important domains even when an overall target is reached.
When response is inadequate, check adherence, actual exposure, intolerance and whether pain reflects ongoing inflammation, structural limitation, mechanical disease or nociplastic mechanisms. Reconsider diagnostic confidence before repeatedly changing mechanisms. Conversely, a normal biomarker should not erase demonstrable synovitis. Ask what the patient can now do, what remains difficult and how much rescue treatment is required.
In sustained control, treatment reduction may be discussed with monitoring and a flare plan. A successful consultation leaves a clear target, a reason for the chosen intervention and the finding that would change the next decision. Shared family biology provides orientation; the individual phenotype determines care.
Interpreting treatment response → Professional access required
Sources and further reading
- van der Heijde D et al. ASAS-defined axSpA nomenclature. 2024.
- Rudwaleit M et al. ASAS axial classification criteria: validation and final selection. Ann Rheum Dis. 2009;68:777–783.
- de Winter J et al. Sacroiliac MRI in healthy individuals, runners and postpartum women. Arthritis Rheumatol. 2018;70:1042–1048.
- ASAS. Recommendations for requesting and reporting imaging in suspected axSpA.
- Ramiro S et al. ASAS–EULAR axSpA recommendations: 2022 update. Ann Rheum Dis. 2023;82:19–34.
- ACR/SAA/SPARTAN. 2026 axSpA guideline summary, posted June 24, 2026.
- Coates LC et al. GRAPPA PsA recommendations 2021. Nat Rev Rheumatol. 2022;18:465–479.
- Gossec L et al. EULAR PsA recommendations: 2023 update. Ann Rheum Dis. 2024;83:706–719.
- EULAR physical activity recommendations: 2025 update. Ann Rheum Dis. 2026;85:1026–1038.
- Rüegg L et al. EULAR reproduction, pregnancy and lactation recommendations: 2024 update. Ann Rheum Dis. 2025;84:910–926.
- FDA. Safety warnings for selected JAK inhibitors.